Now showing items 1-4 of 4

    • Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. 

      Mateo, J; Cheng, HH; Beltran, H; Dolling, D; Xu, W; Pritchard, CC; Mossop, H; Rescigno, P; Perez-Lopez, R; Sailer, V; Kolinsky, M; Balasopoulou, A; Bertan, C; Nanus, DM; Tagawa, ST; Thorne, H; Montgomery, B; Carreira, S; Sandhu, S; Rubin, MA; Nelson, PS; de Bono, JS (2018-05)
      BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. OBJECTIVE: To determine ...
    • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 

      Brahmer, JR; Rodríguez-Abreu, D; Robinson, AG; Hui, R; Csőszi, T; Fülöp, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Zhang, J; Lubiniecki, GM; Deitz, AC; Rangwala, R; Reck, M (2017-12)
      BACKGROUND: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer ...
    • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. 

      Rebbeck, TR; Friebel, TM; Friedman, E; Hamann, U; Huo, D; Kwong, A; Olah, E; Olopade, OI; Solano, AR; Teo, S-H; Thomassen, M; Weitzel, JN; Chan, TL; Couch, FJ; Goldgar, DE; Kruse, TA; Palmero, EI; Park, SK; Torres, D; van Rensburg, EJ; McGuffog, L; Parsons, MT; Leslie, G; Aalfs, CM; Abugattas, J; Adlard, J; Agata, S; Aittomäki, K; Andrews, L; Andrulis, IL; Arason, A; Arnold, N; Arun, BK; Asseryanis, E; Auerbach, L; Azzollini, J; Balmaña, J; Barile, M; Barkardottir, RB; Barrowdale, D; Benitez, J; Berger, A; Berger, R; Blanco, AM; Blazer, KR; Blok, MJ; Bonadona, V; Bonanni, B; Bradbury, AR; Brewer, C; Buecher, B; Buys, SS; Caldes, T; Caliebe, A; Caligo, MA; Campbell, I; Caputo, SM; Chiquette, J; Chung, WK; Claes, KBM; Collée, JM; Cook, J; Davidson, R; de la Hoya, M; De Leeneer, K; de Pauw, A; Delnatte, C; Diez, O; Ding, YC; Ditsch, N; Domchek, SM; Dorfling, CM; Velazquez, C; Dworniczak, B; Eason, J; Easton, DF; Eeles, R; Ehrencrona, H; Ejlertsen, B; EMBRACE; Engel, C; Engert, S; Evans, DG; Faivre, L; Feliubadaló, L; Ferrer, SF; Foretova, L; Fowler, J; Frost, D; Galvão, HCR; Ganz, PA; Garber, J; Gauthier-Villars, M; Gehrig, A; GEMO Study Collaborators; Gerdes, A-M; Gesta, P; Giannini, G; Giraud, S; Glendon, G; Godwin, AK; Greene, MH; Gronwald, J; Gutierrez-Barrera, A; Hahnen, E; Hauke, J; HEBON; Henderson, A; Hentschel, J; Hogervorst, FBL; Honisch, E; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, A; Jakubowska, A; James, P; Janavicius, R; Jensen, UB; John, EM; Vijai, J; Kaczmarek, K; Karlan, BY; Kast, K; Investigators, K; Kim, S-W; Konstantopoulou, I; Korach, J; Laitman, Y; Lasa, A; Lasset, C; Lázaro, C; Lee, A; Lee, MH; Lester, J; Lesueur, F; Liljegren, A; Lindor, NM; Longy, M; Loud, JT; Lu, KH; Lubinski, J; Machackova, E; Manoukian, S; Mari, V; Martínez-Bouzas, C; Matrai, Z; Mebirouk, N; Meijers-Heijboer, HEJ; Meindl, A; Mensenkamp, AR; Mickys, U; Miller, A; Montagna, M; Moysich, KB; Mulligan, AM; Musinsky, J; Neuhausen, SL; Nevanlinna, H; Ngeow, J; Nguyen, HP; Niederacher, D; Nielsen, HR; Nielsen, FC; Nussbaum, RL; Offit, K; Öfverholm, A; Ong, K-R; Osorio, A; Papi, L; Papp, J; Pasini, B; Pedersen, IS; Peixoto, A; Peruga, N; Peterlongo, P; Pohl, E; Pradhan, N; Prajzendanc, K; Prieur, F; Pujol, P; Radice, P; Ramus, SJ; Rantala, J; Rashid, MU; Rhiem, K; Robson, M; Rodriguez, GC; Rogers, MT; Rudaitis, V; Schmidt, AY; Schmutzler, RK; Senter, L; Shah, PD; Sharma, P; Side, LE; Simard, J; Singer, CF; Skytte, A-B; Slavin, TP; Snape, K; Sobol, H; Southey, M; Steele, L; Steinemann, D; Sukiennicki, G; Sutter, C; Szabo, CI; Tan, YY; Teixeira, MR; Terry, MB; Teulé, A; Thomas, A; Thull, DL; Tischkowitz, M; Tognazzo, S; Toland, AE; Topka, S; Trainer, AH; Tung, N; van Asperen, CJ; van der Hout, AH; van der Kolk, LE; van der Luijt, RB; Van Heetvelde, M; Varesco, L; Varon-Mateeva, R; Vega, A; Villarreal-Garza, C; von Wachenfeldt, A; Walker, L; Wang-Gohrke, S; Wappenschmidt, B; Weber, BHF; Yannoukakos, D; Yoon, S-Y; Zanzottera, C; Zidan, J; Zorn, KK; Hutten Selkirk, CG; Hulick, PJ; Chenevix-Trench, G; Spurdle, AB; Antoniou, AC; Nathanson, KL (2018-05)
      The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of ...
    • Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. 

      Catenacci, DVT; Tebbutt, NC; Davidenko, I; Murad, AM; Al-Batran, S-E; Ilson, DH; Tjulandin, S; Gotovkin, E; Karaszewska, B; Bondarenko, I; Tejani, MA; Udrea, AA; Tehfe, M; De Vita, F; Turkington, C; Tang, R; Ang, A; Zhang, Y; Hoang, T; Sidhu, R; Cunningham, D (2017-11)
      BACKGROUND: Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab ...